![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
MV Relling, R Evans, C Dass, DM Desiderio and J Nemec
Pharmaceutical Division, St. Jude Children's Research Hospital, Memphis, Tennessee.
Although teniposide (VM26) and etoposide (VP16) are eliminated mostly by nonrenal mechanisms, their cytochrome P450 metabolism in humans has not been reported. Our objective was to determine the affinity and capacity of P450 O-demethylation of VM26 and VP16 in a variety of human livers. Formation of catechols of VM26 and VP16 was detected in 24 and 26 of 26 liver microsomal preparations, respectively, with wide variability in maximum catechol formation rates from VM26 (41-fold) and VP16 (39-fold range), even among normal livers. Maximal activity measurements at 500 microM substrate were lower for VM26 catechol formation (mean = 1.5 nmol/mg/hr) than for VP16 catechol (mean = 3.2 nmol/mg/hr) in 26 livers (P less than .001). Maximal activities for VP16 and VM26 O-demethylation, and ethoxycoumarin O-deethylation were significantly higher in normal than in diseased livers. No differences were found in activities related to age, sex or race of the liver donor. In all five livers tested over a range of substrate concentrations, Km (19.7, 23.2, 43.5, 30.1 and 22.0 microM) and Vmax values (1.0, 1.2, 4.4, 8.2 and 4.0 nmol/mg/hr) for VM26 were lower compared to values for VP16 (Km = 60.2, 115.1, 87.3, 42.1 and 81.9 microM; Vmax = 1.4, 3.3, 10.3, 27.5 and 10.1 nmol/mg/hr). Despite higher VP16 catechol formation, VM26 underwent greater overall reduced nicotinamide adenine dinucleotide phosphate-dependent metabolism than VP16, consistent with greater nonrenal clearance of VM26 in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  X. Zhuo, N. Zheng, C. A. Felix, and I. A. Blair KINETICS AND REGULATION OF CYTOCHROME P450-MEDIATED ETOPOSIDE METABOLISM Drug Metab. Dispos., September 1, 2004; 32(9): 993 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zheng, C. A. Felix, S. Pang, R. Boston, P. Moate, J. Scavuzzo, and I. A. Blair Plasma Etoposide Catechol Increases in Pediatric Patients Undergoing Multiple-Day Chemotherapy with Etoposide Clin. Cancer Res., May 1, 2004; 10(9): 2977 - 2985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF]
|
|
|
|
|
|
F. Innocenti, L. Iyer, J. Ramírez, M. D. Green, and M. J. Ratain Epirubicin Glucuronidation Is Catalyzed by Human UDP-Glucuronosyltransferase 2B7 Drug Metab. Dispos., April 13, 2001; 29(5): 686 - 692. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. Blanco, P. L. Harrison, W. E. Evans, and M. V. Relling Human Cytochrome P450 Maximal Activities In Pediatric versus Adult Liver Drug Metab. Dispos., April 1, 2000; 28(4): 379 - 382. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. E. Burgio, M. P. Gosl, and a. P. J. McNamara Effects of P-glycoprotein Modulators on Etoposide Elimination and Central Nervous System Distribution J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 911 - 917. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. A. Felix, A. H. Walker, B. J. Lange, T. M. Williams, N. J. Winick, N.-K. V. Cheung, B. D. Lovett, P. C. Nowell, I. A. Blair, and T. R. Rebbeck Association of CYP3A4 genotype with treatment-related leukemia PNAS, October 27, 1998; 95(22): 13176 - 13181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kawashiro, K. Yamashita, X.-J. Zhao, E. Koyama, M. Tani, K. Chiba, and T. Ishizaki A Study on the Metabolism of Etoposide and Possible Interactions with Antitumor or Supporting Agents by Human Liver Microsomes J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1294 - 1300. [Abstract] [Full Text]
|
|
|
|
|
|
X.-J. Zhao, T. Kawashiro, and T. Ishizaki Mutual Inhibition between Quinine and Etoposide by Human Liver Microsomes. Evidence for Cytochrome P4503A4 Involvement in Their Major Metabolic Pathways Drug Metab. Dispos., February 1, 1998; 26(2): 188 - 191. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
